DNMT3A and cyclic hematopoiesis: To explore the relevance of our findings in human CH, we designed and optimized a new prime editing strategy to introduce the R882H mutation into the DNMT3A gene in purified CD34+ HSPCs from human cord blood (CB) samples as conventional homology-directed repair (HDR)-based CRISPR/Cas9 editing strategies are highly inefficient in human HSPCs22.